Literature DB >> 24569605

Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia.

Christine Hofmann1, Hermann Girschick2, Etienne Mornet3, Doris Schneider4, Franz Jakob4, Birgit Mentrup4.   

Abstract

Hypophosphatasia (HPP) is a clinically heterogeneous rare, inherited disorder of bone and mineral metabolism with extensive allelic heterogeneity in the ALPL gene. In this report, we present a family with heterozygous parents (maternal p.(Glu191Lys), paternal p.(Gly334Asp) mutations in the ALPL gene) and four children (one genotypically normal, one heterozygous carrier and two compound heterozygous) showing an unexpected high phenotypic variability. One of the compound heterozygous showed clinical symptoms of the mild childhood form mainly affecting the teeth. The other one was more seriously affected with severe failure to thrive, delayed motor development, need for oxygen supply and profound mineralization deficit compatible with an infantile form of HPP. Functional in vitro studies identified p.(Glu191Lys) as mild (68%, no dominant-negative effect) and p.(Gly334Asp) as severely affected allele (1.2%, dominant-negative effect). In vitro simulation of the children's genetic status showed a residual AP activity of 29%, while the biochemical AP activity in the serum was comparably reduced in both children (22 and 36 U/l). This family report indicates that mapping ALPL mutations within the gene does not necessarily help to predict the clinical severity of the phenotype. Therefore, results of prenatal diagnostics have to be interpreted with caution and prenatal genetic diagnosis and counseling for HPP should be provided within an experienced multidisciplinary team. Research about other confounding factors is urgently needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569605      PMCID: PMC4169536          DOI: 10.1038/ejhg.2014.10

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  10 in total

1.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

Review 2.  Purinergic signalling: from normal behaviour to pathological brain function.

Authors:  Geoffrey Burnstock; Ute Krügel; Maria P Abbracchio; Peter Illes
Journal:  Prog Neurobiol       Date:  2011-09-01       Impact factor: 11.685

3.  Outcome of perinatal hypophosphatasia in manitoba mennonites: a retrospective cohort analysis.

Authors:  Edward C W Leung; Aizeddin A Mhanni; Martin Reed; Michael P Whyte; Hal Landy; Cheryl R Greenberg
Journal:  JIMD Rep       Date:  2013-04-12

4.  Enzyme-replacement therapy in life-threatening hypophosphatasia.

Authors:  Michael P Whyte; Cheryl R Greenberg; Nada J Salman; Michael B Bober; William H McAlister; Deborah Wenkert; Bradley J Van Sickle; Jill H Simmons; Terence S Edgar; Martin L Bauer; Mohamed A Hamdan; Nick Bishop; Richard E Lutz; Mairead McGinn; Stanley Craig; Jean N Moore; John W Taylor; Robert H Cleveland; William R Cranley; Ruth Lim; Tom D Thacher; Jill E Mayhew; Matthew Downs; José Luis Millán; Alison M Skrinar; Philippe Crine; Hal Landy
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

5.  Correlations of genotype and phenotype in hypophosphatasia.

Authors:  L Zurutuza; F Muller; J F Gibrat; A Taillandier; B Simon-Bouy; J L Serre; E Mornet
Journal:  Hum Mol Genet       Date:  1999-06       Impact factor: 6.150

6.  Functional characterization of a novel mutation localized in the start codon of the tissue-nonspecific alkaline phosphatase gene.

Authors:  B Mentrup; C Marschall; F Barvencik; M Amling; H Plendl; F Jakob; C Beck
Journal:  Bone       Date:  2011-03-16       Impact factor: 4.398

7.  A homoallelic Gly317-->Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites.

Authors:  C R Greenberg; C L Taylor; J C Haworth; L E Seargeant; S Philipps; B Triggs-Raine; B N Chodirker
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

8.  Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia.

Authors:  P S Henthorn; M Raducha; K N Fedde; M A Lafferty; M P Whyte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 9.  Vitamin D status: measurement, interpretation, and clinical application.

Authors:  Michael F Holick
Journal:  Ann Epidemiol       Date:  2008-03-10       Impact factor: 3.797

10.  Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles.

Authors:  Delphine Fauvert; Isabelle Brun-Heath; Anne-Sophie Lia-Baldini; Linda Bellazi; Agnès Taillandier; Jean-Louis Serre; Philippe de Mazancourt; Etienne Mornet
Journal:  BMC Med Genet       Date:  2009-06-06       Impact factor: 2.103

  10 in total
  22 in total

Review 1.  Clinical management of hypophosphatasia.

Authors:  Nick Bishop
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

2.  Low-energy trauma-induced intercondylar femoral fracture.

Authors:  Mathias Aeby; Tobias Wyss; Birgit Mentrup; Erdmute Kunstmann; Franz Jakob; Daniel Aeberli
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

3.  Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted Next Generation Sequencing.

Authors:  Agnès Taillandier; Christelle Domingues; Clémence De Cazanove; Valérie Porquet-Bordes; Sophie Monnot; Tina Kiffer-Moreira; Agnès Rothenbuhler; Pascal Guggenbuhl; Catherine Cormier; Geneviève Baujat; Françoise Debiais; Yline Capri; Martine Cohen-Solal; Philippe Parent; Jean Chiesa; Anne Dieux; Florence Petit; Joelle Roume; Monica Isnard; Valérie Cormier-Daire; Agnès Linglart; José Luis Millán; Jean-Pierre Salles; Christine Muti; Brigitte Simon-Bouy; Etienne Mornet
Journal:  Mol Genet Metab       Date:  2015-09-30       Impact factor: 4.797

4.  Genetic analysis of adults heterozygous for ALPL mutations.

Authors:  Agnès Taillandier; Christelle Domingues; Annika Dufour; Françoise Debiais; Pascal Guggenbuhl; Christian Roux; Catherine Cormier; Bernard Cortet; Valérie Porquet-Bordes; Fabienne Coury; David Geneviève; Jean Chiesa; Thierry Colin; Elaine Fletcher; Agnès Guichet; Rose-Marie Javier; Michel Laroche; Michael Laurent; Ekkehart Lausch; Bruno LeHeup; Cédric Lukas; Georg Schwabe; Ineke van der Burgt; Christine Muti; Brigitte Simon-Bouy; Etienne Mornet
Journal:  J Bone Miner Metab       Date:  2017-12-13       Impact factor: 2.626

Review 5.  Hypophosphatasia.

Authors:  Agnès Linglart; Martin Biosse-Duplan
Journal:  Curr Osteoporos Rep       Date:  2016-06       Impact factor: 5.096

6.  Clinical, radiographic and biochemical characteristics of adult hypophosphatasia.

Authors:  T Schmidt; H Mussawy; T Rolvien; T Hawellek; J Hubert; W Rüther; M Amling; F Barvencik
Journal:  Osteoporos Int       Date:  2017-05-25       Impact factor: 4.507

7.  Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Authors:  Lothar Seefried; Jasmin Baumann; Sarah Hemsley; Christine Hofmann; Erdmute Kunstmann; Beate Kiese; Yue Huang; Simon Chivers; Marie-Anne Valentin; Babul Borah; Ronenn Roubenoff; Uwe Junker; Franz Jakob
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

8.  Tissue-nonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl(-/-) mouse model of infantile hypophosphatasia.

Authors:  Jin Liu; Hwa Kyung Nam; Cassie Campbell; Kellen Cristina da Silva Gasque; José Luis Millán; Nan E Hatch
Journal:  Bone       Date:  2014-07-09       Impact factor: 4.398

9.  Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.

Authors:  Michael P Whyte; Cheryl Rockman-Greenberg; Keiichi Ozono; Richard Riese; Scott Moseley; Agustin Melian; David D Thompson; Nicholas Bishop; Christine Hofmann
Journal:  J Clin Endocrinol Metab       Date:  2015-11-03       Impact factor: 5.958

Review 10.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.